Compare NSPR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | CRBP |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 202.6M |
| IPO Year | N/A | N/A |
| Metric | NSPR | CRBP |
|---|---|---|
| Price | $1.93 | $9.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.50 | ★ $50.29 |
| AVG Volume (30 Days) | 101.4K | ★ 513.0K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,779,000.00 | N/A |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $75.45 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.04 | N/A |
| 52 Week Low | $1.59 | $4.64 |
| 52 Week High | $3.80 | $20.56 |
| Indicator | NSPR | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 34.73 |
| Support Level | $1.74 | $9.44 |
| Resistance Level | $2.00 | $11.64 |
| Average True Range (ATR) | 0.12 | 0.74 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 53.85 | 12.16 |
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.